GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
South Korea Index MSCI Ishares (EWY) [hlAlert]

Rating:
Buy EWY
down 25.96 %

South Korea Index MSCI Ishares (EWY) rated Buy with price target $78 by Standpoint Research

Posted on: Monday,  Jun 30, 2014  12:00 AM ET by Standpoint Research

Standpoint Research rated Buy South Korea Index MSCI Ishares (AMEX: EWY) on 06/30/2014, when the stock price was $65.02.
Since then, South Korea Index MSCI Ishares has lost 25.96% as of 08/27/2015's recent price of $48.14.
If you would have followed this Standpoint Research's recommendation on EWY, you would have lost 25.96% of your investment in 423 days.

iShares MSCI South Korea Index Fund (the Fund) seeks to provide results that correspond to the price and yield performance of publicly traded securities in the aggregate in the South Korean market, as measured by the MSCI Korea Index (the Index). The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. The Index seeks to measure the performance of the South Korean equity market. Index is a capitalization-weighted index that aims to capture 85% of the (publicly available) total market capitalization. Component companies are adjusted for available float and must meet objective criteria for inclusion to the Index. Index is reviewed quarterly. The investment adviser of the Fund is Barclays Global Fund Advisors (BGFA). BGFA is the subsidiary of Barclays Global Investors, N.A.

Standpoint Research provides independent equity research that is free from the conflicts of asset management, investment banking, proprietary trading, and fee-for-research arrangements. We provide thorough analysis, diagnostics and forecasts on domestic and international equities and markets backed by alpha-generating variables back-tested on many years of data. Standpoint Research currently advises and sells its research to pension funds, hedge funds and asset management firms. Wall Street analysts have an optimistic bias, while we are more objective. In fact some of the variables in our model that are looked at as positives by Wall Street actually carry negative weight in our model. We have a strict discipline that includes running our proprietary 155-variable valuation and diagnostics model with a personal and subjective overlay that has been proven to add value. The effectiveness is demonstrated through our impressive track record of recommendations.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
6/30/2014 12:00 AM Buy
None
65.02 78.00
as of 10/17/2014
1 Week up  0.58 %
1 Month down  -11.36 %
3 Months down  -11.13 %
1 YTD down  -12.64 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy